Which of these fields of Active and Healthy Ageing are addressed by your initiative?
Health literacy and patient empowerment, Personalized health management, Prevention and early diagnosis of functional and cognitive decline.
If none of the above, answer here:
Please describe if and how your stakeholders (cooperation partners, funders, users, etc.) have been participating in defining the problem and developing the solution.
It is widely agreed that a multidisciplinary approach to dementia deterrence is required. While there is some agreement over the broad areas that impact on dementia risk, less is known about how these factors interact. In-MINDD has gathered together leading experts in dementia prevention in a Delphi exercise to rank a spectrum of risk factors and agree a combinatorial model to predict dementia risk. Our cooperation partners in MU are currently validating several iterations of this model against an existing population sample (n=1200) to identify a model that combines the expertise of the Delphi team with the documented outcomes from this dataset. Next steps in developing the solution will include (i) translating this risk model into a user friendly tool that provides a personalized risk quotient and (ii) feasibility testing of the In-MINDD system. These activities will be conducted by partners in DCU, MU, GU, and UNSA, with each having clearly defined roles at various stages. Input will also be sought from selected general practices in the partner countries to co-design, develop and test the In-MINDD system in order to understand how both practitioners and patients use the tool.
Has your solution been tested in trials, experimentations, or pilot projects? If yes, please describe the process and outcome.
In the coming months our risk profiler and supportive online environment will be implemented in a random group of 600 individuals from the general public in up to 20 general practices from the 4 countries involved in this project. The feasability study will enable the team to evaluate the effectiveness of In-MINDD in relation to risk factor reduction, as well as test its usability in both routine practice and in the lives of those who use it.
What barriers might hinder the success of your initiative? How do you plan to overcome them?
1) In-MINDD aims to incorporate new technology into the everyday lives of primary care staff and individuals deemed at risk of developing dementia. Such routine embedding is not guaranteed. In order to address this, we will attend to the inherent workability and routinisation of the tool into the person’s life and primary care provider’s work, using a recognized social theory, Normalisation Process Theory (NPT). In-MINDD will apply NPT and extensive consultation to ensure that new dementia prevention tools are actually usable and valuable in a clinical setting.
2) Failure to recruit sufficient numbers of doctors and patients. We address this potential low risk barrier by leveraging the strong existing relationships our partners have with doctors who have access to large patient groups to ensure adequate numbers. Additionally, we have planned a robust education framework for GPs to engage them in the importance of dementia risk reduction.